Correction to: Intensive Care Med https://doi.org/10.1007/s00134-020-05991-x

The original version of this article unfortunately contained mistakes. There is an incorrect unit of IL-6 in Fig. 1 and Supplementary Table 1. It should be pg/mL rather than ng/mL. The corrected Fig. 1 and Supplementary Table 1 can be found below. The authors apologize for the mistakes.

Fig. 1
figure 1

a Age distribution of patients with confirmed COVID-19; b key laboratory parameters for the outcomes of patients with confirmed COVID-19; c interval from onset of symptom to death of patients with confirmed COVID-19; d summary of the cause of death of 68 died patients with confirmed COVID-19

Supplementary Table 1: Summary of clinical features and laboratory results of the patients with confirmed COVID-19

 

Normal Range

Died

(N = 68)

Discharged

(N = 82)

p-value

Demographics

    

Age, years

 

67 (15-81)

50 (44-81)

<0.001

Sex

    

Male

 

49 (72%)

53 (65%)

 

Female

 

19 (28%)

29 (35%)

 

Comorbidities

 

43 (63%)

34 (41%)

0.01

Hypertension

 

29 (43%)

23 (28%)

0.07

Cardiovascular disease

 

13 (19%)

0

<0.001

Diabetes

 

12 (18%)

13 (16%)

0.88

Cerebrovascular disease

 

7 (10%)

5 (6%)

0.49

Chronic obstructive pulmonary disease

 

2 (3%)

1 (1%)

0.59

Chronic kidney disease

 

2 (3%)

0

0.20

Malignancy

 

2 (3%)

1 (1%)

0.59

Chronic liver disease

 

1 (1%)

3 (4%)

0.63

Connective tissue disease

 

1 (1%)

0

0.45

Signs and Symptoms

    

Fever

 

59 (87%)

68 (83%)

0.67

Cough

 

51 (75%)

59 (72%)

0.81

Sputum production

 

29 (43%)

25 (30%)

0.17

Fatigue

 

15 (22%)

22 (27%)

0.63

Myalgia

 

9 (13%)

10 (12%)

1

Haemoptysis

 

3 (4%)

0

0.09

Dyspnea

 

59 (87%)

51 (62%)

0.001

Respiratory failure

 

58 (85%)

13 (16%)

<0.001

ARDS

 

55 (81%)

7 (9%)

<0.001

Acute kidney injury

 

21 (31%)

2 (2%)

<0.001

Infection

 

11 (16%)

1 (1%)

0.002

Treatments

    

ICU admission

 

30 (44%)

11 (13%)

<0.001

High flow nasal cannula

 

31 (46%)

10 (12%)

<0.001

Non-invasive mechanical ventilation

 

46 (68%)

5 (6%)

<0.001

Invasive mechanical ventilation

 

25 (37%)

0

<0.001

ECMO

 

7 (10%)

0

0.003

CRRT

 

5 (7%)

0

0.02

Prone position mechanical ventilation

 

3 (4%)

0

0.09

Antiviral treatment

 

33 (49%)

55 (67%)

0.05

Antibiotic treatment

 

63 (93%)

80 (98%)

0.66

Antifungal treatment

 

12 (18%)

5 (6%)

0.04

Glucocorticoid treatment

 

31 (46%)

22 (27%)

0.02

Time from onset of symptom to start of Glucocorticoid treatment, days

 

11.7 (6.9)

11.4 (4.4)

0.89

Time from hospital admission to start of Glucocorticoid treatment, days

 

1.5 (1.2)

3.2 (2.7)

0.01

Glucocorticoid treatment duration, days

 

7.2 (6.7)

7.0 (5.0)

0.92

Supportive therapy

 

45 (66%)

18 (22%)

<0.001

Length of stay, days

 

7.4 (5.5)

12.3 (4.4)

<0.001

Laboratory Findings

    

Time from onset of symptom to test, days

 

11.6 (6.8)

9.8 (4.3)

0.07

White blood cell count, × 109/L

3.50-9.50

10.62 (4.76)

6.76 (3.49)

<0.001

Lymphocyte count, × 109/L

1.10-3.20

0.60 (0.32)

1.42 (2.14)

<0.001

Haemoglobin, g/L

130.0-175.0

127.0 (16.7)

127.6 (16.3)

0.82

Platelet count, × 109/L

125.0-350.0

173.6 (67.7)

222.1 (78.0)

<0.001

Albumin, g/L

35.0-52.0

28.8 (3.8)

32.7 (3.8)

<0.001

Alanine aminotransferase, U/L

9.0-50.0

170.8 (991.6)

48.68 (83.1)

0.35

Aspartate aminotransferase, U/L

15.0-40.0

288.9 (1875.5)

40.7 (57.8)

0.31

Total bilirubin, μmol/L

0.0-26.0

18.1 (10.7)

12.8 (6.8)

0.001

Blood urea nitrogen, mmol/L

3.1-8.0

8.65 (4.5)

5.11 (2.1)

<0.001

Creatinine, umol/L

59.0-104.0

91.2 (56.2)

72.1 (22.2)

0.02

Creatine kinase, U/L

50.0-310.0

319.4 (838.5)

231.7 (862.3)

0.56

Lactate dehydrogenase, U/L

120.0-250.0

905.8 (2619.1)

297.9 (110.4)

0.08

Cardiac troponin, pg/mL

2.0-28.0

30.3 (151.0)

3.5 (6.2)

<0.001

Myoglobin, ng/mL

0.0-146.9

258.9 (307.6)

77.7 (136.1)

<0.001

C-reactive protein, mg/L

0.0-5.0

126.6 (106.3)

34.1 (54.5)

<0.001

Interleukin-6, pg/mL

0.0-7.0

11.4 (8.5)

6.8 (3.61)

<0.001

Serum ferritin, ng/mL

21.8-274.7

1297.6 (1030.9)

614.0 (752.2)

<0.001

  1. Data are n (%), n/N (%), mean (SD), and median (IQR). When the data were normally distributed, continuous variables were then described using median and interquartile range (IQR) values.
  2. ARDS = acute respiratory distress syndrome. ECMO = extracorporeal membrane oxygenation. ICU = intensive care unit. CRRT = continuous renal replacement therapy.